
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical is expected to continue its growth trajectory driven by a strong financial profile and focus on key areas such as recurring revenue, cost-cutting, and international expansion. The company's recent earnings beat and raised guidance further solidify its positive outlook. Additionally, GMED's investments in spinal robotics technology and imaging systems position them well for future success in the medical device industry.
Bears say
Globus Medical is facing potential upside from faster spine market growth, higher sales in Enabling Technologies, and maintained margins; however, downside risks such as slower uptake of robotics and imaging and lower product traction may result in a slightly below market performance. Additionally, risks from competition, staffing issues, macro factors, and the possibility of the GMED/Nuvasive merger not meeting expectations, make the stock a risky bet for investors. With a 2027E EBITDA multiple of ~8x, slightly above the low 5-year NTM EV/EBITDA multiple (~7.5x), the projected price target is $75.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares